It impairs its tumor-suppressive functions, resulting in the constant activation of PI3K/Akt signaling and drug resistance to HER2 inhibitor (trastuzumab) in HER2-positive breast carcinomas (Gallardo et al., 2012). This evidence concerns the gene ERBB2 and breast carcinoma.